Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO

Table 2 Reasons for termination of therapy with Benepali^® (multiple answers were possible)

	n=83	Median survival time (95% CI) in years
Ongoing therapy, n (%)	54 (65.1%)
Therapy terminated, n (%)	29 (34.9%)	3.6 (1.8–3.6)
Reason for termination
Adverse event, n (%)	8 (9.6%)
Inactive disease, n (%)	4 (4.8%)
Ineffectiveness, n (%)	10 (12.1%)
Other^a, n (%)	7 (8.4%)

^aPregnancy (2), patient request (1), Crohn’s disease (1), desire to conceive a child (1), subjective pain during injection (1), unknown (1)

ISSN: 1478-6362